Differentiated thyroid cancer: millions spent with no tangible gain?
- Luis Furuya-Kanamori1,
- Art Sedrakyan2,3,
- Adedayo A Onitilo4,
- Nasser Bagheri2,
- Paul Glasziou5 and
- Suhail A R Doi1⇑
- 1Department of Population Medicine, College of Medicine, Qatar University, Doha, Qatar
- 2Research School of Population Health, Australian National University, Canberra, ACT, Australia
- 3Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York, USA
- 4Department of Hematology/Oncology, Marshfield Clinic Weston Center, Weston, Wisconsin, USA
- 5Centre for Research in Evidence Based Practice, Bond University, Gold Coast, QLD, Australia
- Correspondence should be addressed to S A R Doi: sardoi{at}gmx.net
-
Figure 1
Observed (markers) and modeled (dashed lines) incidence per 100,000 for DTC (circles), thyroidectomies (squares) and DTC-specific mortality (triangles) over time in females. Gray shaded area represents the excess (potentially avoidable) thyroidectomies performed due to the increase in diagnosis over the last decade and the excess in surgery-related health care expenditure associated with this.
-
Figure 2
Observed (markers) and modeled (dashed lines) incidence per 100,000 for DTC (circles), thyroidectomies (squares) and DTC-specific mortality (triangles) over time in males. Gray shaded area represents the excess (potentially avoidable) thyroidectomies performed due to the increase in diagnosis over the last decade and the excess in surgery-related health care expenditure associated with this.
- © 2018 Society for Endocrinology
